Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.56 |
| ▸ | CA1 | P00915 | 10/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843264 | 0.91 | NR1H4 (0.50) | CA2CA1NR1H4EPHX2 | |
| SCHEMBL6842454 | 0.90 | RORC (0.51) | CA2CA1NR1H4EPHX2 | |
| SCHEMBL6843221 | 0.87 | ALDH1A1 (0.55) | CA2NR1H4EPHX2CA12CA9 | |
| SCHEMBL6843234 | 0.87 | NR1H4 (0.62) | NR1H4EPHX2 | |
| SCHEMBL6844739 | 0.87 | CA2 (0.55) | CA2CA1NR1H4EPHX2CA12 | |
| SCHEMBL6192905 | 0.86 | RAB9A (0.54) | NR1H4 | |
| SCHEMBL6842501 | 0.85 | NR1H4 (0.54) | NR1H4EPHX2 | |
| SCHEMBL6842510 | 0.85 | EPHX2 (0.54) | NR1H4EPHX2 | |
| SCHEMBL6843449 | 0.85 | NR1H4 (0.53) | CA2CA1NR1H4EPHX2 | |
| SCHEMBL6843355 | 0.85 | NR1H4 (0.53) | NR1H4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | CA2 982/4885CA1 2024/4885NR1H4 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.